Goodwin Procter represented Intellia Therapeutics, while Latham & Watkins LLP represented the underwriter in the offering.Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
